ASH 2017 Annual Meeting Highlights in Multiple Myeloma

Key ASH Takeaways, Plus Daratumumab in the Relapsed/Refractory Setting – Sagar Lonial, MD, FACP – Run Time: 5:24 Begin

Anti-BCMA CAR-T Cell Therapy in RRMM and RVd Lite in Transplant Ineligible MM – Noopur Raje, MD – Run Time: 7:50 Begin

Monotherapy GSK2857916, an Anti-BCMA Antibody in RRMM – Adam D. Cohen, MD – Run Time: 7:19 Begin

Ixazomib in the Maintenance Setting – Robert Z. Orlowski, MD, PhD – Run Time: 6:44 Begin

Future Treatments in RRMM: Isatuximab and Melflufen – Paul G. Richardson, MD – Run Time: 5:33 Begin

Highlights from the ASPIRE and PETHEMA/GEM2012 Trials – Jesús San Miguel, MD, PhD – Run Time: 10:34 Begin